Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 278.00K | 288.00K | 227.60K | 737.00K | 1.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 278.00K | 288.00K | 227.60K | 737.00K | 1.03M |
| Cost of Revenue | -95.50K | -99.40K | -106.00K | 108.60K | 276.00K |
| Gross Profit | 373.40K | 387.20K | 333.50K | 628.40K | 751.80K |
| SG&A Expenses | 1.46M | 1.50M | 1.10M | 932.00K | 994.70K |
| Depreciation & Amortization | 79.20K | 70.10K | 61.50K | 51.60K | 44.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.62M | 1.58M | 1.12M | 1.16M | 1.34M |
| Operating Income | -1.34M | -1.29M | -894.70K | -425.10K | -313.90K |
| Income Before Tax | -1.45M | -1.38M | -981.00K | -606.00K | -502.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.45 | -1.38 | -0.98 | -0.61 | -0.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.45M | -1.38M | -981.00K | -606.00K | -502.50K |
| EBIT | -1.34M | -1.29M | -894.70K | -425.10K | -313.90K |
| EBITDA | -1.31M | -1.25M | -858.20K | -386.80K | -278.80K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 387.38M | 371.24M | 356.39M | 354.29M | 351.65M |
| Average Diluted Shares Outstanding | 387.38M | 371.24M | 356.39M | 356.23M | 353.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |